Monday, May 14, 2012

OncoMed Files for $115M IPO; FDA Panel Backs Gilead Quad Pill - May 14, 2012

Having trouble viewing this email? View in Browser.
BioSpace GenePool
   Monday, May 14, 2012 Advertising Information
subscriptions Search Jobs news hotbeds careerfairs
Facebook  |  Linked In  |  Twitter  |  RSS  |  Subscribe

TOP SPONSOR

Join us Tuesday, May 22nd at 7:30 for a Breakfast Presentation at the Biomarker World Congress in Philadelphia

Dr. Eric Schaeffer, Director, Neuroscience Clinical Biomarkers, Bristol-Myers Squibb


Please click here for more information.
Top Stories 
•  OncoMed Pharmaceuticals, Inc. Files for $115 Million IPO More...
•  FDA Panel Backs Gilead Sciences, Inc. (GILD) Quad Pill More...
•  Maxygen, Inc. (MAXY) Gets $30 Million Payment From Bayer HealthCare (BAY) More...
•  Stiefel Laboratories Receives FDA Approval of Fabior™ Foam, 0.1% More...
•  Ventrus Biosciences, Inc.  (VTUS) Unveils Positive Results of Its Phase 3 Trial of Diltiazem; Stock Rises +2.19(20.00%) @ 10:26AM EDT More...
•  Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Phase III Crohn's Disease Trial Meets Primary Endpoints More...
•  Roche (RHHBY) Bets on an Alzheimer's Drug More...
•  Opko Health, Inc. Catches Investors' Attention With Alzheimer's Test More...
More Top News
Don't Miss This

Choose a CRO Partner Who Understands Your Unique Development World.

Whether you're investigating an apparatus, instrument, machine or other type of device, our Medical Device Business Unit knows your success hinges upon highly specialized regulatory, reimbursement programs, safety and marketing support. Operating on high-quality systems, we can prepare those key documents that will ultimately clear your product for marketplace entry.

Even after your commercial launch, we're here to help propel your device to that next level. From developing a reimbursement strategy to meeting post-marketing surveillance requirements, we offer the added value of a long-term relationship that endures throughout every phase of your device's lifecycle .

Visit Theorem to find out more.
Featured Stories
•  American Society of Clinical Oncology Preview: Eight Cancer Drugs to Watch at the Big Show More...
•  Red Wine Compound Can Combat Alzheimer's, Georgetown University Medical Center Study More...
•  Vitamin K2: New Hope for Parkinson's Patients? Flanders Institute for Biotechnology Study More...
•  Maternal Gluten Sensitivity Linked to Schizophrenia Risk in Children, Johns Hopkins University Study More...
•  High-Fat Diet Lowered Blood Sugar and Improved Blood Lipids in Diabetics, Linkping University Study More...
•  Blood Pressure Drugs Don't Protect Against Colorectal Cancer, Cancer Reveals More...
•  Novel Approach to Stimulate Immune Cells, Rutgers University Study More...
•  Combo Therapy Reverses Diabetes in Mice, University of Florida Study More...
Tower: Facebook
  More Featured News
Event of the day

SCIENCE FOR MANAGERS, offered in association with Johns Hopkins Medical School is designed to provide executives and managers with a practical understanding of the scientific and development foundations in the life sciences. You will learn the science behind the industry and the breakthrough technologies so as to communicate and perform more effectively in this complex environment.

DATES: Sept 19-21, 2012

Please click here for more information.
Top Jobs
Multiple Regions (SF, LA, Cleveland, NYC)

Corcept Therapeutics
Medical Science Liaison
Conduct one-on-one healthcare professional education. Provide pro-active support of Corcept products related to education, and appropriate communication triaging of TLs, and the core patient support services.

Pharm Country (Bedminster, New Jersey)

Allergan Inc.
Senior Statisticial Programmer - Systems Development
Will provide specialized knowledge and support to carry out systems development activities in support of one or more clinical research studies. Providing leadership and/or support for creating and maintaining systems used to analyze and report trials data.

Genetown (Lexington, Massachusetts)

Shire
Principal Scientist - Late Stage Formulation
Will lead a group of scientists and engineers involved in late stage pharmaceutical development of Shire HGT's products. The scope of the work includes formulation development and support of late phase clinical and commercial manufacturing processes.

Rocky Bio (Tucson, Arizona)

Ventana Medical Systems, Inc.
Director, Regulatory Affairs
Responsible for leading the day-to-day activities of Regulatory Affairs with specific emphasis on global regulatory submission strategy, regulatory submissions, and interaction with global regulatory authorities related to companion diagnostic projects.

BioMidwest (Chicago, Illinois)

Takeda Pharmaceuticals
Risk Manager
Responsible for the development, implementation and administration of the company's risk management function. This position will provide thought leadership to identify and assess the various risks to Takeda's assets and evaluate how these risks can be prevented, assumed, transferred or insured.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!
BioSpace Career Fairs

Biotech Bay

Biotech Bay Career Fair

Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Bay area.

Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.)

Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research.

Job seekers may register here.

Biotech Bay Career Fair, Burlingame, CA May 29, 2012

More information about BioSpace's Career Fairs

BioSpace White Paper
Biotech Career Fairs For Job Seekers 101: Control Your Experience
By June Salvati, BioSpace Director of Events and Corporate Services
Company of the day

Merck Frosst Canada Ltd.
MaRS Centre - Suite 250
101 College Street
Toronto, Ontario M5G 1L7 Canada

Merck Frosst Canada Ltd. is a research-driven pharmaceutical company discovering, developing, and marketing a broad range of innovative medicines to improve human health. The Company boasts a long record of innovation and its scientific discoveries have led to medicines alleviating suffering, and prolonging and enhancing the lives of Canadians and people around the world.

More Company Profiles
Free Resources
FREE Subscription to ALN World

ALN World provides the latest updates on international resources, products, and information to design, build, and equip today's research animal facilities.
Contact Us

Post Your: News | Jobs | Company Profile | Event | Advertising / Sponsorship

BioSpace Inc.
6465 South Greenwood Plaza, Suite 400
Centennial, Colorado 80111 U.S.A.
Phone: 877-277-7585
Fax: 800-595-2929
BioSpace Inc.
90 New Montgomery Street, Suite 414
San Francisco, California 94105 U.S.A.
Phone: 877-277-7585
Fax: 415-576-9217

Send questions and comments to the BioSpace News Beat Team.

Editor & Publisher: Rosemary Do
Editorial & Production Staff: Lana Ho, Maysa Darwish, Tammy Liu, Michelle Wong

BioSpace.com - Life. Science. Community.
Legal Notice

• BioSpace is a registered trademark of BioSpace, Inc.
• Please distribute this e-cast freely.
• Credit any excerpts as follows:
Copyright 2012 BioSpace http://www.biospace.com
• While BioSpace and its agents used their best efforts in collecting and preparing the information published herein, we do not assume, and hereby disclaim, any liability for any loss or damage caused by errors or omissions, whether such errors or omissions resulted from negligence, accident or other causes.
Subscribe/Unsubscribe
If someone forwarded this news to you and you'd like to receive your own copy FREE of charge, simply Subscribe here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.



No comments: